These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36557156)

  • 1. A Hydrodynamic Approach to the Study of HIV Virus-Like Particle (VLP) Tangential Flow Filtration.
    Wolf T; Rosengarten J; Härtel I; Stitz J; Barbe S
    Membranes (Basel); 2022 Dec; 12(12):. PubMed ID: 36557156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of hollow fiber tangential flow filtration for the recovery and concentration of HIV virus-like particles produced in insect cells.
    Negrete A; Pai A; Shiloach J
    J Virol Methods; 2014 Jan; 195():240-6. PubMed ID: 24157258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Process intensification for high yield production of influenza H1N1 Gag virus-like particles using an inducible HEK-293 stable cell line.
    Venereo-Sanchez A; Simoneau M; Lanthier S; Chahal P; Bourget L; Ansorge S; Gilbert R; Henry O; Kamen A
    Vaccine; 2017 Jul; 35(33):4220-4228. PubMed ID: 28648546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of high shear rates on the average hydrodynamic diameter measured in biomimetic HIV Gag virus-like particle dispersions.
    Wolf T; Calisan KK; Stitz J; Barbe S
    Front Bioeng Biotechnol; 2024; 12():1367405. PubMed ID: 38860137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downstream process design for Gag HIV-1 based virus-like particles.
    Lorenzo E; Miranda L; Gòdia F; Cervera L
    Biotechnol Bioeng; 2023 Sep; 120(9):2672-2684. PubMed ID: 37148527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of EV71 virus-like particle purification processes.
    Lin SY; Chiu HY; Chiang BL; Hu YC
    Vaccine; 2015 Nov; 33(44):5966-73. PubMed ID: 25939279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Process monitoring framework for cross-flow diafiltration-based virus-like particle disassembly: Tracing product properties and filtration performance.
    Hillebrandt N; Vormittag P; Dietrich A; Hubbuch J
    Biotechnol Bioeng; 2022 Jun; 119(6):1522-1538. PubMed ID: 35170757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling and simulation of anion-exchange membrane chromatography for purification of Sf9 insect cell-derived virus-like particles.
    Ladd Effio C; Hahn T; Seiler J; Oelmeier SA; Asen I; Silberer C; Villain L; Hubbuch J
    J Chromatogr A; 2016 Jan; 1429():142-54. PubMed ID: 26718185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of Virus-Like-Particle Vaccine and Reporter Assay for Zika Virus.
    Garg H; Sedano M; Plata G; Punke EB; Joshi A
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28794019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensifying Continuous Production of Gag-HA VLPs at High Cell Density Using Stable Insect Cells Adapted to Low Culture Temperature.
    Fernandes B; Correia R; Alves PM; Roldão A
    Front Bioeng Biotechnol; 2022; 10():917746. PubMed ID: 35845394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural Insight into CVB3-VLP Non-Adjuvanted Vaccine.
    Hankaniemi MM; Baikoghli MA; Stone VM; Xing L; Väätäinen O; Soppela S; Sioofy-Khojine A; Saarinen NVV; Ou T; Anson B; Hyöty H; Marjomäki V; Flodström-Tullberg M; Cheng RH; Hytönen VP; Laitinen OH
    Microorganisms; 2020 Aug; 8(9):. PubMed ID: 32846899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formalin treatment increases the stability and immunogenicity of coxsackievirus B1 VLP vaccine.
    Hankaniemi MM; Stone VM; Andrejeff T; Heinimäki S; Sioofy-Khojine AB; Marjomäki V; Hyöty H; Blazevic V; Flodström-Tullberg M; Hytönen VP; Laitinen OH
    Antiviral Res; 2019 Nov; 171():104595. PubMed ID: 31491431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of the Electrokinetic Properties of HIV-Based Virus-Like Particles.
    Wolf T; Grau C; Rosengarten JF; Stitz J; Wilkens J; Barbe S
    Langmuir; 2024 Mar; 40(9):4762-4771. PubMed ID: 38385169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymer-grafted chromatography media for the purification of enveloped virus-like particles, exemplified with HIV-1 gag VLP.
    Pereira Aguilar P; Schneider TA; Wetter V; Maresch D; Ling WL; Tover A; Steppert P; Jungbauer A
    Vaccine; 2019 Nov; 37(47):7070-7080. PubMed ID: 31300289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Affinity chromatography for virus-like particle manufacturing: Challenges, solutions, and perspectives.
    Ma J; Tian Z; Shi Q; Dong X; Sun Y
    J Chromatogr A; 2024 Apr; 1721():464851. PubMed ID: 38574547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.
    Schweneker M; Laimbacher AS; Zimmer G; Wagner S; Schraner EM; Wolferstätter M; Klingenberg M; Dirmeier U; Steigerwald R; Lauterbach H; Hochrein H; Chaplin P; Suter M; Hausmann J
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28331098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Designing Chimeric Virus-like Particle-based Vaccines for Human Papillomavirus and HIV: Lessons Learned.
    Eto Y; Saubi N; Ferrer P; Joseph J
    AIDS Rev; 2019; 21(4):218-232. PubMed ID: 31834327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization, Production, Purification and Characterization of HIV-1 GAG-Based Virus-like Particles Functionalized with SARS-CoV-2.
    Boix-Besora A; Lorenzo E; Lavado-García J; Gòdia F; Cervera L
    Vaccines (Basel); 2022 Feb; 10(2):. PubMed ID: 35214708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Scalable chromatography-based purification of virus-like particle carrier for epitope based influenza A vaccine produced in Escherichia coli.
    Lagoutte P; Mignon C; Donnat S; Stadthagen G; Mast J; Sodoyer R; Lugari A; Werle B
    J Virol Methods; 2016 Jun; 232():8-11. PubMed ID: 26947397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Process development for cross-flow diafiltration-based VLP disassembly: A novel high-throughput screening approach.
    Hillebrandt N; Vormittag P; Dietrich A; Wegner CH; Hubbuch J
    Biotechnol Bioeng; 2021 Oct; 118(10):3926-3940. PubMed ID: 34170511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.